VolitionRx Limited (NYSE American: VNRX) has announced a breakthrough in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA using its Capture-Seq platform. This advancement overcomes a longstanding challenge in the field: distinguishing cancer DNA from healthy cell-free DNA in blood samples. The company reported strong early validation results, including no false positives and successful detection across initial study cohorts, supporting the potential of the technology as a novel biomarker approach.
The significance of this development lies in its potential applications for multi-cancer early detection and minimal residual disease monitoring. These applications represent a combined total addressable market of approximately $36 billion. The ability to isolate cancer DNA with such high purity could lead to more accurate, less invasive diagnostic tools that detect cancer earlier and monitor treatment effectiveness more precisely. Early detection and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.
Volition is a multi-national company focused on advancing the science of epigenetics and is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
The company added that it is in active discussions with global diagnostic and liquid biopsy companies to accelerate development and commercialization of the platform. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information, visit the company's website at https://volition.com/.
This announcement was distributed through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions. For more information about InvestorWire, please visit https://www.InvestorWire.com.
